Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRAYDYE-Trial
2025-523166-24-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of 6QC-ICG in breast cancer and ductal carcinoma in situ (DCIS) (4 arms), sponsored by Leiden University Medical Center. Primary endpoints: Local tolerability assessment, LIGS score and 7 more. Planned start Dec 2025; status: authorised.
02
Drugs
6QC-ICG
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on 2025-523166-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523166-24-00.